Divis Laboratories shares gained 2.06% to ₹7,397.50 after the company reported strong annual results for the year ending March 2026. The firm achieved a 60% growth in net profit over the last two years, reflecting improved operational performance. Investors are now focused on the upcoming board meeting scheduled for August 1, 2026, where the company will review its first-quarter financial results.
Detailed Coverage
Divis Laboratories, a key player in the Indian pharmaceutical sector, saw its stock price rise by 2.06 percent on Monday, closing at ₹7,397.50. This movement followed the release of financial results for the fiscal year ending March 2026, which showed strong growth in both revenue and profitability.
Financial Growth Trends
The company’s performance for the quarter ending March 2026 highlighted a consolidated revenue of ₹2,831.00 Crore, compared to ₹2,604.00 Crore in the previous quarter. Net profit for the same period rose to ₹751.00 Crore, up from ₹583.00 Crore. This growth was also reflected in the Earnings Per Share (EPS), which improved to ₹28.34 from ₹21.98.
On an annual basis, the company reported revenue of ₹10,560.00 Crore for FY26, an increase from ₹9,360.00 Crore in FY25. The annual net profit reached ₹2,568.00 Crore, compared to ₹2,191.00 Crore the previous year. Over a two-year window, the company’s revenue expanded by 34.61 percent, while net profit grew by 60.50 percent, moving from ₹7,845.00 Crore and ₹1,599.00 Crore respectively in 2024.
Operational Context and Upcoming Triggers
Divis Laboratories continues to be a major participant in the Active Pharmaceutical Ingredients (API) and contract manufacturing space. As a constituent of the Nifty Next 50, its performance is often tracked alongside other large pharmaceutical companies. A consistent history of dividend payouts has also been a focal point for long-term shareholders.
The next important event for the company is a board meeting scheduled for August 1, 2026. During this meeting, the management will discuss and approve the unaudited financial results for the quarter ending June 30, 2026. Investors often monitor these quarterly updates to assess whether the growth momentum from the previous fiscal year is being sustained in the current operating environment, particularly given potential fluctuations in raw material costs and global demand for pharmaceutical ingredients.